Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with ECF, IC, or FOLFOX in Metastatic Esophageal and GE Junction Cancer
NCT00381706Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2006
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in esophageal cancer and gastroesophageal junction cancer (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Tumor Response Rate. Started Sep 2006; status: completed.
02
Drugs
KL-140
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00381706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381706.